PubMed:23592772 / 1842-1959 JSONTXT

{"project":"sentences","denotations":[{"id":"T13","span":{"begin":0,"end":117},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"DisGeNET","denotations":[{"id":"T8","span":{"begin":82,"end":87},"obj":"gene:4790"},{"id":"T9","span":{"begin":112,"end":116},"obj":"disease:C1335302"}],"relations":[{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"23592772-12#82#87#gene4790","span":{"begin":82,"end":87},"obj":"gene4790"},{"id":"23592772-12#112#116#diseaseC1335302","span":{"begin":112,"end":116},"obj":"diseaseC1335302"}],"relations":[{"id":"82#87#gene4790112#116#diseaseC1335302","pred":"associated_with","subj":"23592772-12#82#87#gene4790","obj":"23592772-12#112#116#diseaseC1335302"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"mondo_disease","denotations":[{"id":"T14","span":{"begin":112,"end":116},"obj":"Disease"}],"attributes":[{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005184"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T13","span":{"begin":112,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"HP:0006725"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T14","span":{"begin":112,"end":116},"obj":"Disease"}],"attributes":[{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005184"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"sentences","denotations":[{"id":"T13","span":{"begin":0,"end":117},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T13","span":{"begin":0,"end":117},"obj":"Sentence"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}

{"project":"HP-phenotype","denotations":[{"id":"T13","span":{"begin":112,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"HP:0006725"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Our data indicate that hyper-O-GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC."}